| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 647 | 2020 |
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ... PloS one 6 (4), e19234, 2011 | 207 | 2011 |
| Natural history of non-small-cell lung cancer with bone metastases D Santini, S Barni, S Intagliata, A Falcone, F Ferraù, D Galetta, L Moscetti, ... Scientific reports 5 (1), 1-9, 2015 | 114 | 2015 |
| Response of thymoma to cetuximab G Farina, MC Garassino, M Gambacorta, N La Verde, G Gherardi, ... The Lancet Oncology 8 (5), 449-450, 2007 | 93 | 2007 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 84 | 2018 |
| Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis MC Garassino, V Torri, G Michetti, ML Dico, N La Verde, S Aglione, ... Lung Cancer 72 (3), 378-383, 2011 | 72 | 2011 |
| Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis E Galfrascoli, S Piva, M Cinquini, A Rossi, N La Verde, A Bramati, ... Digestive and Liver Disease 43 (4), 286-294, 2011 | 71 | 2011 |
| Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives S Gori, M Barberis, MA Bella, F Buttitta, E Capoluongo, P Carrera, ... Critical Reviews in Oncology/Hematology 140, 67-72, 2019 | 70 | 2019 |
| Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with … A Bramati, S Girelli, G Farina, MC Dazzani, V Torri, A Moretti, S Piva, ... Journal of bone and mineral metabolism 33, 119-124, 2015 | 60 | 2015 |
| Efficacy of biological agents in metastatic triple-negative breast cancer A Bramati, S Girelli, V Torri, G Farina, E Galfrascoli, S Piva, A Moretti, ... Cancer treatment reviews 40 (5), 605-613, 2014 | 58 | 2014 |
| T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer A Fabi, D Alesini, E Valle, L Moscetti, R Caputo, M Caruso, L Carbognin, ... The Breast 41, 137-143, 2018 | 56 | 2018 |
| The clinical value of nutritional care before and during active cancer treatment G Aprile, D Basile, R Giaretta, G Schiavo, N La Verde, E Corradi, T Monge, ... Nutrients 13 (4), 1196, 2021 | 51 | 2021 |
| Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world … L Cantini, G Mentrasti, GL Russo, D Signorelli, G Pasello, E Rijavec, ... ESMO open 7 (2), 100406, 2022 | 48 | 2022 |
| Osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates: how the knowledge of a phenomenon can change its evolution N La Verde, C Bareggi, M Garassino, K Borgonovo, P Sburlati, D Pedretti, ... Supportive care in cancer 16, 1311-1315, 2008 | 46 | 2008 |
| The prognostic role of tumor size in early breast cancer in the era of molecular biology AA Kasangian, G Gherardi, E Biagioli, V Torri, A Moretti, E Bernardin, ... PloS one 12 (12), e0189127, 2017 | 45 | 2017 |
| Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study G Bon, L Pizzuti, V Laquintana, R Loria, M Porru, C Marchiò, E Krasniqi, ... Journal of Experimental & Clinical Cancer Research 39, 1-14, 2020 | 42 | 2020 |
| Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor … R Campanella, L Guarnaccia, C Cordiglieri, E Trombetta, M Caroli, ... Cells 9 (2), 294, 2020 | 40 | 2020 |
| NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel+ trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer SA Jacobs, A Robidoux, J Abraham, JM Pérez-Garcia, N La Verde, ... Breast Cancer Research 21, 1-11, 2019 | 40 | 2019 |
| Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis MC Garassino, K Borgonovo, A Rossi, A Mancuso, O Martelli, A Tinazzi, ... Anticancer research 29 (7), 2691-2701, 2009 | 39 | 2009 |
| Development and clinical indications of cetuximab R Labianca, N La Verde, MC Garassino The International journal of biological markers 22 (1_suppl4), 40-46, 2007 | 39 | 2007 |
Marina Chiara GarassinoThe University of ChicagoVerified email at medicine.bsd.uchicago.edu
